Multicenter Phase II Trial Evaluating Pembrolizumab for the Treatment of Classical or Endemic Kaposi Disease [Essai de Phase II Multicentrique évaluant le Pembrolizumab Dans le Traitement de la Maladie de Kaposi Classique ou endémique]

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 16 Mar 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary)
Indications Kaposi's sarcoma
Focus Proof of concept; Therapeutic Use
Acronyms KAPKEY

Most Recent Events

10 Mar 2022 Primary endpoint has been met (Best Overall Response Rate ), as per as per Results published in the Lancet Oncology
10 Mar 2022 Status has been changed to completed, as per Results published in the Lancet Oncology
10 Mar 2022 Final Results published in the Lancet Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight